Drug Trial Radar · NCT02145000
Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger
Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,586
Actual
Start
Jun 2014
Primary completion
Dec 2015
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- EpicentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medecins Sans Frontieres, Netherlands; Serum Institute of India Pvt. Ltd.; FORSANI (Forum Santé Niger); Ministère de la Santé Publique, Niger; Children's Hospital Medical Center, Cincinnati
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a double-blinded, randomized, placebo-controlled, trial with two groups of infants receiving vaccine or placebo to assess the efficacy and safety of BRV-PV. Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9 will be administered at 4 week intervals between doses. The first administration will occur at 6-8 weeks of age. We hypothesize a difference in vaccine efficacy of three doses of BRV-PV vaccine vs. placebo against severe rotavirus gastroenteritis in healthy infants in Niger. Active surveillance for gastroenteritis episodes will be conducted throughout the trial. Surveillance for adverse events will be carried out among all children from the time of first vaccination and 28 days post-Dose 3. Surveillance for all serious adverse events, including intussusception and death, will be conducted on all participants until they each reach two years of age. To assess the effect of prenatal nutrition supplementation on infant immune response to the BRV-PV vaccine, study villages in the immunogenicity sub-cohort will be randomized in a 1:1:1 ratio to provide pregnant women with daily iron-folate, multiple micronutrients or a lipid-based nutrition supplement. Infants of participating women, if eligible at 6-8 weeks of age, will be randomized in a 1:1 ratio to receive three doses of vaccine or placebo and enter the main trial as part of the immunogenicity sub-cohort.
Conditions
- Severe Rotavirus Gastroenteritis
Interventions
Rotavirus vaccine (BRV-PV)Biological
Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
PlaceboBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Laboratory-confirmed episode of severe rotavirus gastroenteritisTime frame: From 28 days post-Dose 3 until 117 cases are accrued or when all participating infants reach 2 years of age if 117 cases are not attained
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Madarounfa Health District
Madarounfa, Maradi Region, Niger
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.